GlassScriptPhysician profile
Monica Purificacio Robles
NPI 1306953294
$709.44
in general payments reported to CMS, 2019-2025
15 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2021: $70.14 · 2022: $19.45 · 2023: $39.65 · 2024: $240 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $134.00 | 2023-2025 | Vraylar |
| Allergan, INC. | $132.93 | 2019 | |
| Axsome Therapeutics, INC. | $126.30 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $69.07 | 2019-2021 | |
| Neuronetics, INC. | $43.05 | 2019 | |
| Lundbeck LLC | $32.17 | 2025 | Rexulti |
| Indivior INC. | $26.97 | 2024 | Sublocade |
| Almatica Pharma LLC | $23.18 | 2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $22.00 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $21.75 | 2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.45 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.09 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.71 | 2019 | |
| Shire North American Group INC | $14.29 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.48 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.